First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Trial Profile

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2015

At a glance

  • Drugs Melphalan flufenamide (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Lymphoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Oncopeptides
  • Most Recent Events

    • 13 Nov 2015 New trial record
    • 10 Nov 2015 Results published in the Investigational New Drugs
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top